Physician
Internal Medicine
Dr. Donald Maxwell, MD
|
|
Give Review
Doctor Donald Maxwell, MD practices Internal Medicine. He graduated from University of Connecticut School of Medicine. University of Connecticut School of Medicine is ranked 60 in research and 49 in primary care medicine Dr. Donald Maxwell is a published doctor and has 53 publications published. The lastest was: 'Cardiorespiratory effects of O-isobutyl S-[2-(diethylamino)-ethyl] methylphosphonothioate -- a structural isomer of VX.' Donald Maxwell accepts Medicare payments and is registered with Medicare.gov.
Publications
- Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase.
- Effects of subacute pyridostigmine administration on mammalian skeletal muscle function.
- Cholinesterase studies with (R) (+)- and (S)(-)-5-(1,3,3-trimethylindolinyl)-N-(1-phenylethyl)carbamate.
- Studies of the amplification of carbaryl toxicity by various oximes.
- Contribution of direct actions of the oxime HI-6 in reversing soman-induced muscle weakness in the rat diaphragm.
- Kinetic properties of soluble and membrane-bound acetylcholinesterase from electric eel.
- Effects of repeated injection of sublethal doses of soman on behavior and on brain acetylcholine and choline concentrations in the rat.
- In vitro oxidation of the hydrolysis product of sulfur mustard, 2,2'-thiobis-ethanol, by mammalian alcohol dehydrogenase.
- Enzymes as pretreatment drugs for organophosphate toxicity.
- Toxicodynamic modeling of highly toxic organophosphorus compounds.
- Cresylbenzodioxaphosphorin oxide pretreatment alters soman-induced toxicity and inhibition of tissue cholinesterase activity of the rat.
- Temperature effects in cyanolysis using elemental sulfur.
- Inhibition of rat cerebrum acetylcholinesterase isoenzymes after acute administration of soman.
- The effects of blood flow and detoxification on in vivo cholinesterase inhibition by soman in rats.
- Effect of an anticholinesterase compound on the ultrastructure and function of the rat blood-brain barrier: a review and experiment.
- The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and carboxylesterase activities of the rat.
- Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds.
- Behavioral decrements persist in rhesus monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase.
- Cardiorespiratory effects of O-isobutyl S-[2-(diethylamino)-ethyl] methylphosphonothioate -- a structural isomer of VX.
- The role of glutamate-199 in the aging of cholinesterase.
- A pharmacodynamic model for soman in the rat.
- Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase.
- The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds.
- Hepatic subcellular localization of cresylbenzodioxaphosphorin oxide (CBDP)-sensitive soman binding sites.
- A theoretical model of the competition between hydrolase and carboxylesterase in protection against organophosphorus poisoning.
- Development of a physiologically based model for the toxicokinetics of C(+/-)P(+/-)-soman in the atropinized guinea pig.
- Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates.
- Catalytic antibodies hydrolysing organophosphorus esters.
- Species differences in the negative inotropic effect of acetylcholine and soman in rat, guinea pig, and rabbit hearts.
- Organophosphate skin decontamination using immobilized enzymes.
- Effect of carboxylesterase inhibition on carbamate protection against soman toxicity.
- Effect of endogenous carboxylesterase on HI-6 protection against soman toxicity.
- The role of carboxylesterase in species variation of oxime protection against soman.
- Quantitative structure-activity analysis of acetylcholinesterase inhibition by oxono and thiono analogues of organophosphorus compounds.
- Oxime-induced reactivation of carboxylesterase inhibited by organophosphorus compounds.
- The effect of carboxylesterase inhibition on interspecies differences in soman toxicity.
- The pH dependence of dealkylation in soman-inhibited cholinesterases and their mutants: further evidence for a push-pull mechanism.
- Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning.
- Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase.
- Cholinesterases as scavengers for organophosphorus compounds: protection of primate performance against soman toxicity.
- Amplification of the effectiveness of acetylcholinesterase for detoxification of organophosphorus compounds by bis-quaternary oximes.
- Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases.
- Comparison of oxime reactivation and aging of nerve agent-inhibited monkey and human acetylcholinesterases.
- A structure-activity analysis of the variation in oxime efficacy against nerve agents.
- An in vitro comparative study on the reactivation of nerve agent-inhibited guinea pig and human acetylcholinesterases by oximes.
- Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun.
- Effect of octanol:water partition coefficients of organophosphorus compounds on biodistribution and percutaneous toxicity.
- Acetylcholinesterase inhibition: does it explain the toxicity of organophosphorus compounds?
- A physiologically based pharmacokinetic (PB/PK) model for multiple exposure routes of soman in multiple species.
- Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys.
- Two possible orientations of the HI-6 molecule in the reactivation of organophosphate-inhibited acetylcholinesterase.
- A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphorus poisoning.
Schools
University Of Connecticut
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
University of Connecticut School of Medicine
Drug Facts
| NPI NUMBER | 1740235282 | |
| NPPES Provider LastName | MAXWELL | |
| NPPES Provider FirstName | DONALD | |
| NPPES Provider ZIPCode | 060023119 | |
| NPPES Provider State | CT | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 167.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740235282 |
| Last Name Of The Provider | MAXWELL |
| First Name Of The Provider | DONALD |
| View All |
Similar Doctors
|
|
Dr. Katrina S. Turner, MD |
|
|
Dr. Cameale A. Smart, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Harini Hosain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akwasi Arhin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy Kellerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilberto E. Ramirez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lenworth Ellis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark Josel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert H. Safer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Munish K. Shastri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin J. Fierer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald S. Szabo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert J. Keating III, MD
This Doctor is OpenDoctor Recommended.
|